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Abstract The recent focus on the cystic fibrosis (CF) com-
plex microbiome has led to the recognition that the microbes
can interact between them and with the host immune system,
affecting the disease progression and treatment routes.
Although the main focus remains on the interactions between
traditional pathogens, growing evidence supports the contri-
bution and the role of emergent species. Understanding the
mechanisms and the biological effects involved in
polymicrobial interactions may be the key to improve effec-
tive therapies and also to define new strategies for disease
control. This review focuses on the interactions between mi-
crobe–microbe and host–microbe, from an ecological point of
view, discussing their impact on CF disease progression.
There are increasing indications that these interactions impact
the success of antimicrobial therapy. Consequently, a new
approach where therapy is personalized to patients by taking
into account their individual CF microbiome is suggested.
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Introduction
Cystic fibrosis (CF) is a common lethal disease affecting near-
ly 70,000 people around the world. It is characterized by the
build-up of thick mucus overlying lung epithelial cells, where-
in persistent cycles of chronic infection and inflammation oc-
cur (Gibson et al. 2003; Goss and Burns 2007). The CF air-
ways provide microorganisms with heterogeneous microenvi-
ronments containing varying levels of oxygen, pH, nutrients,
and antibiotics. This heterogeneity contributes largely for the
proliferation of a phylogenetically diverse ecosystem,
influencing the consortia of microbes able to occupy it
(Yang et al. 2011a).
A complex microbiome has been previously described in
the context of CF (e.g., Lopes et al. (2014a)). This microbiome
encompasses species that are believed to be clinically signif-
icant and species thought to be bystanders, i.e., microorgan-
isms for which no direct evidence exists to support their im-
pact in the disease. Pseudomonas aeruginosa is recognized as
the most significant and the most commonly isolated pathogen
in CF infections, worsening CF pulmonary status due to
chronic infections and being responsible for higher fatality
rates (Winstanley and Fothergill 2009). In addition, a small
number of other pathogens, such as Staphylococcus aureus,
Haemophilus influenzae, and the Burkholderia cepacia com-
plex, have been also documented as having repercussions in
disease progression (Alexander and Hudson 2001; Lambert
2002; Lyczak et al. 2002; Yang et al. 2006; Starner et al.
2006; Treggiari et al. 2007; Drevinek and Mahenthiralingam
2010; Kahl 2010; Hauser et al. 2011; Høiby et al. 2011; Huang
and Lynch 2011). Novel molecular technologies have more
recently detected and identified a diverse microbial communi-
ty inhabi t ing CF lungs ( Inqui l inus l imosus and
Dolosigranulum pigrum, etc.) of unexplored relevance in CF
disease (Coenye et al. 2002; Bittar et al. 2008).
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The multispecies microbiome composition in CF is con-
stantly shaped by selective pressures exerted by the niche
characteristics at sites of infection. It is increasingly recog-
nized that the properties of such communities may be distinct
from those of their individual members, due in large part to
interspecies interactions shaping behavior (Faust et al. 2012;
Korgaonkar et al. 2013). This may, in part, explain the lack of
response to conventional therapeutic regimens that primarily
target single causative agents instead of all members in the
community.
Nonetheless, the precise ways under which the many dif-
ferent organisms interact within the CF airways and how these
interactions influence the behavior of the individual species,
the activities of the polymicrobial communities, and the rela-
tionship between host and microbes are poorly understood
questions. Some studies have highlighted the potentially im-
portant roles of such interspecies interactions in disease phe-
notype and clinical outcome of CF infections (e.g., Amin et al.
2010; Chattoraj et al. 2010; Bragonzi et al. 2012; Twomey
et al. 2012; Lopes et al. 2012). Such studies suggest that both
synergistic and antagonistic interactions in mixed-species in-
fections can impact microbial virulence and antibiotic resis-
tance, which most likely will have clinical effects on disease
severity and responses to therapy. Consequently, it is pertinent
that therapeutic/prophylactic strategies should not be limited,
and/or focused only, on the major pathogenic members that
are able to directly cause disease but also on polymicrobial
communities that involve complex interactions among mem-
bers of the CF microbiota.
In a recently published review (Lopes et al. 2014a). we
described the diversity of the CF microbiome and provided a
few examples of possible interactions between different mi-
croorganisms. In here, we consider the collective microbiome
as a potential pathogenic entity in itself, describe in detail the
social behavior within CF communities, highlighting the in-
teractions established among microbes and between microbes
and their host in the context of CF and analyzing whether a
particular community causes or worsens disease, in a manner
analogous to individual pathogens. We conclude that the rela-
tionship between a microbial community and disease is better
understood from an ecological perspective and can improve
clinical understanding, ultimately providing guidelines for an
effective treatment and chronic infection suppression.
Relevant aspects of CF—pathogenesis,
reduced-oxygen environment, and microbial
colonization
CF is a human genetic disorder that results from mutations in
the CF transmembrane conductance regulator (CFTR) gene.
The most prevalent of those mutations (ΔF508) is the deletion
of three nucleotides at the position 508 of the CFTR protein
sequence (Lopes et al. 2014a). The CFTR protein acts as a
channel for the chloride and sodium ions transport across the
cell membranes. Therefore, a dysfunctional CFTR protein
leads to the absence or a decreased chloride secretion,
resulting in an intracellular accumulation of those ions and
ultimately to the depletion of chloride, sodium, and water
from the airway lumen. This causes abnormal thick and vis-
cous secretions and impairs mucociliary clearance in CF air-
ways (Rowe et al. 2005; Davis 2006; Farrell et al. 2008).
The clinical manifestations of CF are quite variable, affect-
ing individuals throughout their entire life. CF-affected indi-
viduals typically have a lifespan of approximately 30–40 years
(Castellani et al. 2008). It is well established that the greatest
contributor to the morbidity and/or mortality is the failure in
lung function that generally occurs in older patients, caused by
the build-up of mucus that clogs the airways and leads to
persistent colonization by different microorganisms (frequent-
ly bacterial species). Hence, recurrent cycles of infections and
inflammation lead to progressive airway and lung damage,
respiratory failure and eventually death (Fig. 1) (Nixon et al.
2001; De Boeck et al. 2006; Boucher 2007).
The existence of steep oxygen gradients within the CF
airwaymucus is well-known, with zones ranging from aerobic
(in the top layers) to completely anaerobic (deeper mucus
layers) (Fig. 2 steps 1–3) (Worlitzsch et al. 2002).
Typically, the airway epithelial cells have a thin and hydrat-
ed mucus layer, located on top of the periciliary liquid layer
(PCL), which enables an efficient mucociliary clearance
(Worlitzsch et al. 2002; Hassett et al. 2002; Boucher 2004).
A normal rate of epithelial O2 consumption (Qo2) produces no
O2 gradients within the thin airway surface liquid (ASL). In
CF, the airway epithelium absorbs the sodium (Na+) and chlo-
ride (Cl−) ions and water from the lumen, depletes the PCL
and slow down or even stop the mucus transport. The in-
creased O2 consumption associated with accelerated CF ion
transport does not generate gradients in the thin biofilm of
ASL, but the persistent mucus hyper secretion leads to the
production of luminal mucus plugs, hence increasing the mu-
cus layer on the epithelial cells and generating steep oxygen
gradients, with zones ranging from aerobic (generally located
at the top) andmicroaerobic and/or even completely anaerobic
(located in the deeper layers) (Worlitzsch et al. 2002; Hassett
et al. 2002; Boucher 2004).
Patients suffering from CF are prone to develop severe
biofilm-related infections that are thought to contribute greatly
to the emergence and dissemination of antibiotic resistance
(Høiby et al. 2010a). The biofilm formation represents a pro-
tective mode of growth that allows microorganisms to survive
in hostile environments and disperse by seeding cells to colo-
nize new niches under desirable conditions (Wei and Ma
2013). P. aeruginosa persists in the CF airways due to its
ability to form biofilms, being considered the key CF patho-
gen (Hassett et al. 2010). P. aeruginosa presents a notorious
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ability to develop resilient biofilms in the form of Bbacterial
aggregates^ within the CF mucus (Fig. 2, steps 4–6)
(Worlitzsch et al. 2002; Hassett et al. 2002; Boucher 2004;
Wei and Ma 2013). The persistence of chronic P. aeruginosa
lung infections in CF patients is due to biofilm-growing mu-
coid strains, protected by alginate overproduction (Høiby et al.
2010b). The persistence of these biofilms into the CF airway
mucus often leads to a high tolerance to many antibiotics
(Borriello et al. 2004). Conventional resistance mechanisms,
such as the presence of a chromosomal β-lactamase, upregu-
lated efflux pumps, and mutations of antibiotic target mole-
cules in the bacteria, have also contributed to the adaptation of
P. aeruginosa biofilms to the CF environment (Høiby et al.
2010b).
Although P. aeruginosa prefers oxygen respiration as the
highest energy-yielding process for growth, it can survive in
the mucus anaerobic zones (Hassett et al. 2002). The ability of
this bacterium to adapt to the oxygen-limited environments is
associated with a drastic physiological change in P.
aeruginosa (e.g., increased alginate production; alterations in
the outer membrane; biofilm development), which contributes
to an increased antibiotic tolerance (Schobert and Jahn 2010).
The alginate produced by the biofilm bacteria in CF lung
infections also provides a physical barrier to host defense sys-
tems (Worlitzsch et al. 2002; Hassett et al. 2002; Boucher
2004).
The complex CF microbiome
Traditional CF microbiology
As stated above, the infections in the CF airway are frequently
polymicrobial (Rogers et al. 2004; Sibley et al. 2006; Bittar
and Rolain 2010). The CF airways offer a favorable environ-
ment for the colonization and proliferation of a large variety of
organisms, including as bacteria, fungi, and viruses, with bac-
terial species being the ones that are more frequently isolated
(Guss et al. 2011).
Traditionally, the detection and identification of microbial
species has relied on culture-based studies, using sputum or
bronchial alveolar lavage samples for microbial detection and
identification (Price et al. 2013). These techniques allow iden-
tification of several key microbial species that contribute to
CF lung infection and disease progression, beginning early in
life with S. aureus and H. influenzae and culminating in
chronic infections caused by P. aeruginosa or B. cepacia
complex species (Table 1) (Razvi et al. 2009; Price et al.
2013).
S. aureus, one of the first pathogens isolated from CF sam-
ples, is the most prevalent pathogen in children and adoles-
cents; however, 40 % of adult patients still remain colonized
(Kahl 2010). S. aureus has the ability to cause chronic infec-
tion (Alexander and Hudson 2001; Kahl 2010; Hauser et al.
2011). H. influenzae is also involved in chronic lung infec-
tions in CF pediatric patients, forming structures consistent
with biofilms even before the onset of clinical signs or symp-
toms of lung disease (Starner et al. 2006). B. cepacia complex
is a group of 18 Burkholderia species infecting 2 to 8 % of
patients with CF, with some of them (B. cenocepacia, B.
multivorans, B. cepacia, and B. dolosa) being highly trans-
missible, presenting pathogenic potential and very high resis-
tance to antibiotic therapy (Yang et al. 2006; Lynch 2009;
Drevinek and Mahenthiralingam 2010).
Approximately 50 % of CF patients are colonized with P.
aeruginosa (Government 2013). which remains the most
common pathogen isolated from CF sputum, being more
prevalent in adults (Folkesson et al. 2012). The presence of
P. aeruginosa in CF airways is highly associated with poor
lung function, morbidity, and mortality of patients. After col-
onization with P. aeruginosa, consecutive episodes of recolo-
nization frequently occur, resulting in a chronic infection that
Fig. 1 Mechanism of the CF pulmonary disease. In the lungs, the
defective chloride ion transport results in the decrease of the volume of
the periciliary fluid, compromising the mucociliary clearance and
triggering the overproduction of dehydrated and viscous mucus. This
leads to the persistent colonization of bacteria in the lungs, and the
physiologic consequences are persistent inflammatory responses,
obstructive lung physiology, respiratory insufficiency, which ultimately
results in death from chronic respiratory failure. Adapted from Kirkby
et al. (2011)
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can persist for years or even never being eradicated in CF
patient lungs (Sousa and Pereira 2014).
Emergent CF microbiology
In addition to the bacterial species documented as CF patho-
gens, recent molecular methodologies have documented com-
plexmicrobial ecosystems in CF samples, with a wide array of
uncommon microorganisms coexisting with traditional path-
ogens acting collectively to facilitate disease progression
(Peters et al. 2012). Figure 3 discloses all the genera of micro-
organisms recovered so far from the respiratory tracts of pa-
tients with CF. The analysis of this figure highlight that almost
120 genera were recovered from CF airways, with a clear
dominance of bacterial genera and only 7 genera of viruses
detected. These microorganisms include bacteria (e.g., I.
limosus, D. pigrum, Stenotrophomonas maltophilia), fungi
(e.g., Aspergillus fumigatus, Candida albicans), and viruses
(e.g., rhinovirus, adenovirus, influenza). In addition,
Worlitzsch and colleagues (2009). identified in a cross-
Fig. 2 aAlterations in mucus of normal epithelial airway cells (Step 1 to
3): (Step 1) On a normal airway epithelia, a thin mucus layer (yellow)
resides on top of the PCL (clear). The presence of the low-viscosity PCL
facilitates efficient mucociliary clearance (denoted by black arrow). A
normal rate of epithelial O2 consumption (Qo2; left) produces no O2
gradients within this thin ASL (denoted by the red bar). (Step 2)
Excessive CF volume depletion (denoted by vertical arrows) removes
the PCL, mucus becomes adherent to epithelial surfaces, and mucus
transport slows/stops (bidirectional black arrow). The raised O2
consumption (left) associated with accelerated CF ion transport does not
generate gradients in thin films of ASL. (Step 3) Persistent mucus
hypersecretion (denoted as mucus secretory gland; gray) with time
increases the height of luminal mucus masses/plugs. The raised CF
epithelial Qo2 generates steep hypoxic gradients (blue color in bar) in
thickened mucus masses. b Schematic model for P. aeruginosa biofilm
in the CFmucus (Step 4 to 6): (Step 4) P. aeruginosa are deposited on the
thickened mucus surfaces and can penetrate the mucus actively (e.g., by
inhalation, flagellum- or pili-dependent motility) and/or passively (due to
mucus turbulence) into the CF mucus. (Step 5) Afterward, P. aeruginosa
start to develop bacterial aggregates (the biofilms), which are protected by
an alginate capsule. In this step, the consumption of O2 is drastically
increased by the bacterial cells, and hypoxic and/or anaerobic pockets
are formed. (Step 6) In the final stages, where O2 is almost depleted,
the bacterial aggregates become highly resistant to the neutrophils and
antibiotics, setting the stage for persistent chronic infection (Worlitzsch
et al. 2002; Hassett et al. 2002; Boucher 2004)
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sectional study of 15 genera of obligate anaerobes in 91 % of
patients suffering fromCF. Tunney and colleagues (2008) also
reported anaerobic species within the genera Prevotella,
Veillonella, Propionibacterium, and Actinomyces, which were
isolated in high numbers (>64 %) in sputum samples from
patients in adulthood. The high numbers of anaerobic bacteria
detected in the CF airways may be a result of oxygen con-
sumption by aerobic pathogens (such as P. aeruginosa) that
often colonize the airways, creating a favorable niche for the
proliferation of anaerobes (Worlitzsch et al. 2002; Yoon et al.
2002). Using molecular methods (16S rRNA gene clone li-
braries and pyrosequencing), Guss and colleagues (2011)
have identified, only in 4 CF sputum samples, more than 60
bacterial genera, including facultative and obligate anaerobes,
oral bacteria, and opportunistic pathogens, many of which
have never before been found in the CF lung. Bittar and
colleagues (2008) identified 53 different bacterial species
from 25 sputum samples. Additionally, standard microbiolog-
ical culture and phenotypic identification of bacteria in spu-
tum from CF patients have been compared to molecular
methods by the use of 16S rDNA amplification, cloning,
and sequencing. Twenty-five sputa from CF patients were
cultured yielding 33 isolates (13 species) known to be patho-
gens during CF. For molecular cloning, 760 clones were se-
quenced (7.2 ± 3.9 species/sputum), and 53 different bacterial
species were identified including 16 species of anaerobes
(30 %). These results indicate that the traditional culture
methods are insufficient to describe the polymicrobial popu-
lations actually present in the CF lung. A recent review pro-
vides a comprehensive understanding of the great complexity
of the microbiome existing in CF, detected and/or identified
employing recent molecular methodologies (Lopes et al.
2014a).
Although the role of some of these emergent microorgan-
isms in the pathogenesis of the disease and their clinical rele-
vance remain unclear, there are already some hints about the
implication of some unusual species in the pathophysiology of
CF (Caraher et al. 2008; Ulrich et al. 2010; Costello et al.
2011; Sherrard et al. 2014; O’Neill et al. 2015; Pustelny
et al. 2015; Benedyk et al. 2015). Further studies of this com-
plex niche by, e.g., metagenomic analysis (Bittar et al. 2008;
Price et al. 2013; Lim et al. 2013; Hauser et al. 2014; Lim et al.
2014) are currently needed to better understand these micro-
bial communities, their implication in treatment and antibiotic
resistance, their role in the development of chronic respiratory
infections, and to identify their clinical significance in order to
find new therapeutic targets.
Ecological perspective of the CF microbiome
Microbial interactions might exist within CF polymicrobial
communities, so it is not surprising that these infections are
increasingly viewed as complex communities of interacting
organisms, with dynamic processes key to their pathogenicity.
Similarly to the relative contribution to clinical status, disease
progression and efficacy of antibiotic therapy by newly iden-
tified members of a polymicrobial community, which remain
to be fully explored, the know-how on the consequences of
the interplay among potential pathogens and/or between them
and their eukaryotic host is also pivotal for understanding and
treat CF-associated infections. These interactions can be me-
diated by a large number of mechanisms, which encompasses
interspecies signaling, metabolite exchange, and cell–cell con-
tact and are often implicated in the modulation of microbial
behavior, ultimately contributing to disease progression and
clinical outcome. In addition, many types of infections are
caused by biofilm-associated microorganisms (Burmølle
et al. 2010). which are harder to eradicate compared with
planktonic exponentially growing cells, due to several factors
operating concurrently (e.g., changed structure and reduced
diffusion rates of the compounds in the biofilm matrix,
changed gene expression pattern, and low growth rates of
the biofilm-encased cells) (Sousa and Pereira 2014).This pro-
tective effect may be further enhanced if multiple species are
present within the biofilm, where the dynamics between the
resident species may potentially evolve and change the vol-
ume and function of the whole biofilm both qualitatively and
quantitatively (Burmølle et al. 2014). In these consortia, mi-
croorganisms frequently communicate via quorum sensing
Table 1 Bacterial species most commonly associated with CF airway
disease
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(QS) complex systems, which play an important role in the
social behavior, regulation of microbial population density,
and expression of virulence factors (e.g., resistance genes
and proteins) among members of a microbial community
(Rutherford and Bassler 2012).
Although particular microbial communities may be associ-
ated with certain clinical outcomes, the heterogeneous nature
of the airway environment (nutrients, as well as physiochem-
ical characteristics, such as oxygen tension, temperature, and
pH) will influence the mix of microbes that are able to occupy
it, through exerting selective pressures. In addition, it is in-
creasingly recognized that the microbes can alter the charac-
teristics of the niche in which they grow, by influencing the
behavior of other colonizing species (such as pathogenicity
(Sibley et al. 2008)), or by directly interacting with the eu-
karyotic host (e.g., by damaging airway epithelia (King 2011)
or triggering inflammation (Essilfie et al. 2012)), as well as the
impact of changes in antibiotic treatment that follow clinical
worsening, such as the type and intensity of antibiotic expo-
sure (Rogers et al. 2013). For instance, Tunney et al. (2011)
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Fig. 3 Genus of microorganisms identified in respiratory tracts of patients with CF (lung image adapted from http://lungdiseasenews.com)
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have reported that substantial shifts in bacterial abundance
within the microbial community can be detected following
antibiotic therapy. However, Stressmann and colleagues
(2012) showed that antibiotic therapy can temporarily perturb
these communities, which tend to return to their pretreatment
configuration following cessation of antibiotics.
The pressures affecting microbiome composition are dy-
namic, and the comprehensive understanding of the drives
of microbial community stability is fundamental for predicting
the way in which a microbiome will respond to perturbation.
Microbial activity will influence the processes that select for
subsequent members of the microbiome; therefore, the infec-
tion by one species can indirectly dictate microbiome compo-
sition (Rogers et al. 2013).
Hence, it becomes imperative to understand the molecular
basis and the biological effect of those interplay processes
within multispecies communities to help improve clinical un-
derstanding and the in-use treatment regimens, devising new
targets and disease control strategies.
An extensive research in recent literature has identified
studies reporting interactions among microbes and between
microbes and their host in the context of CF, which is summa-
rized in Table 2.
The interactions described within Table 2 are divided into
two different categories, synergism and antagonism.
Contrariwise to synergistic interactions, which represent mu-
tual benefit to all species present, antagonistic interactions
result in a negative effect for at least one species. As it is
possible to observe, microorganisms can use simultaneously
different mechanisms to interact with other species, which
may be associated with the niche characteristics and selective
pressures exerted that shaped the behavior and the way in
which the species interact.
The majority of the studies found in the literature (Table 2)
are carried out under in vitro conditions so that the effect of
interaction in the host is only predictive. Although the predic-
tive effects for most microbe–host interactions (most of them
carried out in vivo) are considered negative, some mecha-
nisms involve interactions that can have a predictable positive
effect on the host and thereby be used as a therapeutic ap-
proach. Similarly, molecules that block key signal sensing or
transduction steps in pathogens could represent lead com-
pounds for new drugs.
In any polymicrobial infection, the combined effect of two
or more microbes on the disease progression can be more
dramatic than any of the individuals alone and can display
enhanced pathogen persistence in the infection site, increased
disease severity, and increased antimicrobial resistance in a
phenomenon known as polymicrobial synergism (Dalton
et al. 2011; Peters et al. 2012; Murray et al. 2014).
Synergistic interactions between different bacterial species al-
low reaping benefits that would be unattainable to them as
individual cells, such as increased antibiotic tolerance, biofilm
development, defense against competitors, adaptation to
changing environments, increased tissue damage, and de-
clined pulmonary infection (Jacques et al. 1998; Duan et al.
2003; Dalton et al. 2011). As examples of synergistic interac-
tions occur in the CF context, several authors (Pilkington et al.
2011; Bragonzi et al. 2012) have demonstrated that a higher
number of cells in the biofilm can be produced, which may
have a great impact in antibiotic tolerance.
However, in some cases, the antagonistic interactions
between organisms within a community are unavoidable
due to competition for finite resources, with effects on
the growth or viability of competitors (Harrison 2007).
In CF, these interactions were found, for example, be-
tween P. aeruginosa and the fungal species A. fumigatus
and C. albicans, with the small diffusive molecules se-
creted by P. aeruginosa inhibiting the biofilm formation
of those fungal populations (Hogan et al. 2004; Cugini
et al. 2007; Mowat et al. 2010). and between B.
cenocepacia and C. albicans with QS signal produced
by B. cenocepacia inhibiting the filament formation by
C. albicans (Boon et al. 2008). Bacteria produce many
types of diffusible molecules that can interact with other
bacteria during disease. The various chemical cell-to-cell
signaling mechanisms that are used by bacteria are col-
lectively known as QS systems (Fuqua et al. 1994). a
bacterial cell-to-cell communication process that in-
volves the production, detection, and response to extra-
cellular signaling molecules called autoinducers (AIs)
(Rutherford and Bassler 2012). Some signal molecules
such as autoinducer-2 (AI-2), Pseudomonas Quinolone
Signal (PQS), 2-heptyl-4-hydroxy quinoline N-oxide
(HQNO), and signal molecules of the diffusible signal
factor (DSF) have been found to be produced during the
infection and to influence other bacteria. For example,
the ability to stimulate S. aureus biofilm formation was
strongly associated to the production of HQNO and
PQS by P. aeruginosa isolates (Fugère et al. 2014).
While some studies have revealed the interplay among typ-
ical CF bacteria (Hoffman et al. 2006). only few have reported
the role of emergent species on lung disease chronicity (Lopes
et al. 2014a, 2014b) or the interactions between those atypical
microorganisms with eminent pathogens (Lopes et al. 2012).
mainly when the micorganisms are encased in biofilms.
Recently, Lopes et al. (2012) showed that the CF atypical
bacteria I. limosus and D. pigrum could interact synergistical-
ly with P. aeruginosa, developing dual-species consortia with
increased tolerance to several antibiotics. This suggests that
previously thought clinically insignificant species may influ-
ence the behavior of individual species or even the whole
microbial community. Based on these ecological interactions,
it is strongly suggested to have a focus shift from an individual
species to a polymicrobial community management and that
modeling such multispecies interactions will help to predict
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the effects of new therapeutic interventions, dismissing much
of the current antibiotic therapy empiricism and increasing its
effectiveness.
In addition to microbial–microbial interactions, microbial–
host interactions also exist in CF, and the most significant
features is the ability of the pathogens to deceive or modulate
the multifaceted host response following colonization. The
airway epithelium recognizes and responds to pathogens
through the interaction between host pathogen recognition
receptors and pathogen-associated membrane proteins
(Callaghan and McClean 2012). The airway epithelium is
one of several sources of chemokine interleukin-8 (IL-8)
(Standiford et al. 1990) that acts as the first line of host defense
against pathogens. In CF patients, theΔF508-CFTRmutation
results in increased levels of IL-8 and neutrophils, responsible
for the development of chronic obstructive and inflammatory
lung diseases (Bodas and Vij 2010). Furthermore, neutrophils
resulting in DNA release and increased mucous viscosity
worsen the problem of bacterial attachment (Callaghan and
McClean 2012). Recent studies have demonstrated that the
conventional pathogens P. aeruginosa and B. cenocepacia
can trigger an excessive inflammatory response in the host
(Kotrange et al. 2011; Pilkington et al. 2011; Lorè et al.
2012; Kim et al . 2014) . Deregulat ion of matr ix
metalloproteases (MMPs) in CF is another contributor to CF
lung disease and to bacterial colonization (Pilkington et al.
2011). So, while many of the modifications and adaptations
serve to promote inflammation and to benefit the colonization,
other strategies are used to avoid and minimize the host re-
sponse (Patankar et al. 2013). Additionally, colonization by
multiple pathogens may trigger unknown repercussions in the
host, although it is suspected that for most cases, adverse
effects can occur with greater impact in antibiotic therapy.
The majority of studies about interactions in the
polymicrobial CF community focus on the traditional patho-
gen P. aeruginosa, due to its prevalence in CF lung, its ability
to form biofilms that protect the organism to the host re-
sponses and to numerous antibiotics, and its potential do de-
velop chronic infection. Therefore, more research is needed to
provide a better mechanistic insight into the complex interplay
between potential pathogenic agents, commensal organisms,
and the host response in the polymicrobial infections.
Understanding polymicrobial interactions to better
treat CF
The resistance to antimicrobial agents is currently one of the
major problems in the healthcare setting worldwide (French
2010). Antimicrobial resistance is potentiated in CF patients
due to the extensive use of antimicrobial agents from a young
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When the chronic infection is established, pathogens such
as P. aeruginosa growing as biofilms in the CF lung can ex-
hibit increased resistance to antibiotics (Hassett et al. 2009;
Bjarnsholt et al. 2009; Høiby et al. 2011). In fact, bacteria in
the form of biofilms show increased resistance to several an-
tibiotics when compared to planktonic or free living counter-
parts (Sriramulu et al. 2005). The minimal inhibitory concen-
tration (MIC) and minimal bactericidal concentration (MBC)
of antibiotics to biofilm-growing bacteria may be up to 100–
1000-fold higher compared with planktonic bacteria (Anwar
et al. 1990; Moskowitz et al. 2004).
Apart from the conventional resistance mechanisms pre-
sented by bacteria (e.g., chromosomal beta-lactamase, upreg-
ulated efflux pumps, and mutations in antibiotic target mole-
cules), biofilms also present an extracellular polymeric matrix.
The reduced diffusion of antibiotics through the
exopolysaccharide matrix (alginate, in the case of P.
aeruginosa biofilm) retards the movement of antimicrobial
agents (Costerton 2001; Bagge et al. 2004; Chan et al. 2005;
Anderson and O’Toole 2008; Vettoretti et al. 2009) and con-
tributes for the resistance and/or tolerance of biofilms to the
antimicrobial agents (Høiby et al. 2010a; Sriramulu 2013).
When CF was first described in 1938 (Andersen 1938). the
predicted survival age of patients was only 6 months (Cohen-
Cymberknoh et al. 2011). For patients born in the 1990s,
median survival is now predicted to exceed 40 years, due to
the introduction of multiple therapies that treat the symptoms
of CF (Wilschanski 2013).
Antibiotic therapy for CF patients is directed at preventing,
eradicating, or controlling respiratory infections. The therapy
generally starts with oral and inhaled therapies in an outpatient
setting and the use of intravenous route for patients with se-
vere exacerbations (McCaughey et al. 2012; Sriramulu 2013).
The fluoroquinolones (e.g., ciprofloxacin) are the most
commonly used oral agents to treat acute exacerbations caused
byP. aeruginosa infection (Sriramulu 2013). Other agents that
have long been used by inhalation in CF patient for the treat-
ment of P. aeruginosa lung infection are tobramycin, aztreo-
nam, or colistin (Sriramulu 2013). Current standard care
guidelines for antibiotic recommend in CF patients for most
commonly bacterial species are described in Table 3.
Recently, new antibiotic combinations have been devel-
oped (MacLeod et al. 2009; McCaughey et al. 2012;
McCaughey et al. 2013; Anderson et al. 2013). One example
is the combination of fosfomycin/tobramycin (FTI), an in-
haled antibiotic with broad-spectrum antibacterial activity
for treatment of bacterial respiratory infections. FTI consists
of fosfomycin (F) and tobramycin (T) in a 4:1 weight-to-
weight ratio (w/w); this combination has promising activity
against MRSA and P. aeruginosa with greater activity under
aerobic and physiologically relevant anaerobic conditions,
compared to F or T alone (MacLeod et al. 2009;
McCaughey et al. 2012; McCaughey et al. 2013; Anderson
et al. 2013). Lam and colleagues (2013) reported that
tobramycin inhalation powder (TIP) represents the first dry
powder inhaled antibiotic available for use in CF. TIP was
approved in the USA in 2013 (Fiel 2014). Inhaled antibiotics
have been probably the safest and most effective therapy for P.
aeruginosa chronic lung infection in CF patients (Máiz et al.
2013). The use of inhaled antibiotics allows it to be delivered
directly to the target area, with a lower dose than more con-
ventional oral or intravenous delivery methods, with reduced
Table 3 Antibiotic therapy used
for bacterial species most
commonly associated with CF
airway disease (Döring et al.
2012)
Species Infection phase Antibiotic therapy




Inhaled colistin or tobramycin or aztreonam
Chronic
infection
Two inhaled antibiotics among the following: colistin,
tobramycin, aztreonam
H. influenzae – Oral or intravenous amoxicillin + clavulanic acid
depending on the severity.














Oral rifampicin + fusidic acid.
Chronic
infection
Intravenous vancomycin or teicoplanin or linezolid
B. cepacia – At least two intravenous antibiotics: Intravenous
ticarcillin + clavulanic acid or piperacillin + tazobactam
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systemic absorption and consequently reduced risk of toxic
effects (Traini and Young 2009; Hoppentocht et al. 2014).
With the increased antibiotic resistance in CF patients, the
need for new strategies in the lifelong treatment of pulmonary
infection has to be validated (van Westreenen and Tiddens
2010). In a cross-sectional study, the detection of 2,3-
butanedione in the breath gases of CF patients indicated the
presence of Streptococcus spp. (Whiteson et al. 2014).
Linking together products that are unique to microbial metab-
olism with the genes detected by metagenomic sequences of
microbial communities in sputummay enable development of
biomarkers for early detection of exacerbations.
Lim and colleagues (2014) combined the use of
metagenomic sequencing and clinical microbiology for mon-
itoring polymicrobial infections in individual patients. Their
findings highlighted that information on the predicted resis-
tance of the whole microbial community is perhaps one of the
most useful pieces of information extracted frommetagenome
sequencing, which will be important to understand how quick-
ly antibiotic resistance might change in the microbial commu-
nity. The implementation of metagenomic analysis as a clini-
cal diagnostic tool can give rise to vital information for clini-
cians to prescribe the appropriate antibiotic therapy.
Because CF infection is no longer viewed as being caused
by a single pathogen, antibiotics used to target a small group
of species recognized as key CF pathogens are generally in-
effective when other atypical species are present (Lopes et al.
2012, 2014b) or fail in many cases (Leekha et al. 2011). This
problem is compounded by the huge polymicrobial CF com-
munity and the bacterial interactions occurring in lung. Due to
the complex interactions that result between traditional and
emergent CF pathogens—for instance, a study by Lopes and
colleagues (2012) demonstrated that the association among
atypical and conventional CF bacteria could result in the im-
pact of the antibiotic resistance—a new approach where anti-
biotic therapy is personalized to each patient, based on com-
prehensive microbiological analyses, could be development
for treating lung infections (Short et al. 2014). There is an
increasing appreciation of the polymicrobial nature of many
bacterial infections such as those associated with CF and of
the potentially important role for interspecies interactions in
influencing both bacterial virulence and response to therapy,
as previously discussed in the earlier section. Twomey and
colleagues (2012) demonstrated that antibiotic resistance of
P. aeruginosa biofilms was enhanced in the presence of dif-
fusible signal molecules, produced by Stenotrophomas
maltophilia and B. cenocepacia. On the other hand, a recent
study showed that P. aeruginosa might be responsible for the
protection of S. maltophilia against tobramycin (Pompilio
et al. 2015).
Antivirulence drugs are a new type of therapeutic drug that
target virulence factors, without killing or inhibiting bacterial
growth. Many antivirulence strategies are being explored,
including inhibiting bacterial adhesion to the host cell
(inhibiting biofilm formation), inhibiting cell-to-cell signaling
(known as quorum quenchers by inhibiting QS systems), and
interfering with gene regulation of virulence traits (Rasko and
Sperandio 2010; Rutherford and Bassler 2012; Allen et al.
2014). Other innovative therapeutic approach is the develop-
ment of CFTR-modulating drug as potential treatment for
cystic fibrosis. Ivacaftor is the first licensed CFTR modulator
drug and, although only targets ∼5 % of CF patients, may
indeed be one of many therapeutic agents that point to the
emergence of a new era of personalized medicine (Ramsey
et al. 2011). These drugs will allow treatment of the basic
defect in CF disease and open the door for therapy according
to gene sequencing— t rue personalized medicine
(Wilschanski 2013). Moreover, every person with CF is
unique and requires personalized diagnosis and therapy.
In addition to recognizing the polymicrobial nature of CF
community, understanding the molecular mechanisms and bi-
ological effects from the microbe–microbe and host–microbe
interactions is also crucial to improve therapy regimens and
also define new antimicrobial agents, new targets and strate-
gies for CF disease control. We are facing a postantibiotic era
with limited capability to combat polymicrobial infections.
Conclusions
In the past decades, technological advances in diagnostic tools
have led to the recognition that many infections, including CF,
are far more complex than originally believed. It has become
apparent that, although therapies are focused on the treatment
of the dominant microbial species of an infection, other mi-
crobes may have a profound significance on both the response
to antibiotic therapy and virulence. While microbes–microbes
and microbes–host interactions are not fully understood, it is
suspected that the consequences of such interplay carry out
synergistic and antagonistic effects either for CF treatment or
for antibiotic resistance, ultimately contributing to disease
progress and clinical outcome.
Accordingly, the challenge is now to explore multispecies
biofilms in further detail, by examining their physiology, func-
tion, and underlying mechanisms but specifically enhancing
the focus for microbial–microbial and/or microbial–host inter-
actions in these communities. Understanding the physical and
chemical interactions between microorganisms in these
polymicrobial communities will help to define potential new
targets for disrupting biofilm-community development and, in
cystic fibrosis, affect the ecology of biofilms in the airways of
patients. Since several pathogens employ QS regulation to
express a specific broad range of virulence factors, this has
spurred interest in QS inhibitors as antivirulence drugs.
The medical community is now starting to recognize the
significance of polymicrobial diseases and the major types of
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microbial community interactions associated with human
health and disease. Many traditional therapies are just starting
to take into account the polymicrobial cause of diseases and
the repercussions of treatment and prevention. By taking into
account the complexity of infecting organisms and their inter-
play, it is intended to develop a new approachwhere therapy is
personalized to each patient or to a group of patients. If suc-
cessful, the approach may pave the way for more effective
therapeutic regimens and ultimately contribute to personalized
treatment for these diseases, based on unique microbial profile
of a given patient, and further extrapolate for analogous
polymicrobial infections.
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